TARS
Tarsus Pharmaceuticals, Inc.−$0.68 (0.93%) At close $72.64 · Today
☾After Hours +$0.61 (0.84%) Nov 3, 7:59 PM ET
About TARS
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Cylvex Score
Some risk factors elevated
Multi-factor score. Not a buy/sell signal.
Score history
CalibratingScore history is calibrating — it appears once enough daily scores are recorded.
What goes into the score
6 axes · equal weightThe Cylvex Score is a multi-factor summary for education. Not a buy/sell signal. Not investment advice.